MET gene amplification is identified in 2–5% of gastric cancers [17, 18], 2–4% of esophageal adenocarcinoma (EAC) [5, 12], 1–8% of non-small cell lung cancer (NSCLC) [10, 13, 19], and 2–10% of colorectal cancers [13, 20]. This evidence concerns the gene MET and non-small cell lung carcinoma.